抄録
Glucagon has been shown to depress the gut motility and pancreatic secretion and it has also been reported that glucagon has a beneficial effect on experimental pancreatitis in mice.
The present study investigates whether glucagon administration decreases duodenal moltility and prevents the increase of serum pancreatic enzymes after endoscopic retrograde chlangiopancreatography (ERCP) . ERCP was performed in 29 consecutive cases (18 males and 11 females) , which were divided into two groups. Scopolamine butylbromide was given at a dose of 20 mg to Group B, and glucagon was given at a dose of 1 mg to Group G. Each drug was administered by intramuscular injection before ERCP, and then duodenal motility was evaluated by modified Niwa's criteria : (1 : complete supression to 5 : no supression) . Serum pancreatic enzymes were determined to be suppresed at 0h, 4h and 24h after ERCP.
Result : 1. The glucagon treatment suppressed duodenal motility slightly more than the scopolamine butylbromide treatment (1.5±0.7 vs 2.0±0.4) . 2.Serum lipase levels at 4h after ERCP in patients in Group G were slightly lower than in patients in Group B ; however, there was no differece at 24h between two groups.
In conclusions, the glucagon treatment suppressed duodenal motility sufficiently in ERCP. Further research is needed to determine whether the incidence of postcannulation pancreatitis can be reduced by glucagon.
